Member Profile: The Alliance of Families Fighting Pancreatic Cancer
From left, back: AFFPC Board member Ric Fera with Dr. A. James Moser, co-director of Pancreas Liver Institute and Pancreatic Cancer Research Program at Beth Israel Deaconess Medical Center and associate professor of surgery, Harvard Medical Center. From left, front: Board members Theresa Dukovich, Kendra Haywood, Brigitte Regnier and Debbie Barnes. Not pictured: Board members Jessica Fera and Dr. Ken Grey.
The Alliance of Families Fighting Pancreatic Cancer (AFFPC), based in the United States, is an alliance of families, patients, caregivers, medical researchers, healthcare institutions and organizations united to transform pancreatic cancer treatment by empowering patients with personalized options for better survival and quality of life. The organization was founded in 2012 based on the realization that the families of those affected by pancreatic cancer are the ones who will lead the fight. We have faced pancreatic cancer and joined together to continue the fight.
Our World Pancreatic Cancer Coalition membership helps us connect with survivors, caregivers and other foundations who support our mission, and it helps us increase awareness of the need for personalized treatment options.
Our main aim is to transform pancreatic cancer treatment through front-line research to improve outcomes for all patients. We are especially pleased to support the development of the first-ever clinical biomarker to diagnose and treat pancreatic cancer.
Global demand for better pancreatic cancer diagnosis and treatment options remains high. The AFFPC supports the work of A. James Moser, MD, and his team at the Pancreas and Liver Institute at Beth Israel Deaconess Medical Center (BIDMC) in Boston who are at the forefront of combating this complex disease head-on.
Dr. Moser’s research team works to increase scientific understanding at a molecular level and to increase patient care quality. BIDMC functions at the lead site on Project Survival, a biomarker discovery study led by BIDMC, Berg Pharma and PCRT. By utilizing Berg’s artificial intelligence software, their team is able to synthesize trillions of data points per sample, helping to discover and clinically validate the pancreatic cancer biomarkers. In May 2018, Dr. Moser founded the Pancreas and Liver Institute Disease Registry and Biorepository. This core biorepository aims to create a hub of pancreatic and liver research at BIDMC.